Cell-based high-throughput screening methods

• US 20040253647A1
• Filed: 08/06/2004
• Published: 12/16/2004
• Est. Priority Date: 06/26/2001
• Status: Abandoned Application

• Current Assignee: Research Foundation For Mental Hygiene Incorporated
• Original Assignee: Research Foundation For Mental Hygiene Incorporated
• Inventors: Jiang, Ying, Mathews, Paul M., Nixon, Ralph A., Schmidt, Stephen D.
• Application Number:
  US10/481,954
• Publication Number:
  US 20040253647A1
• Time in Patent Office: Days
• US Class Current: 435/7.2
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/14 for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: G01N 2333/4709 Amyloid plaque core protein
• CPC Class Codes: G01N 2800/2821 Alzheimer
• CPC Class Codes: G01N 33/5008 for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
• CPC Class Codes: G01N 33/5014 for testing toxicity
• CPC Class Codes: G01N 33/502 for testing non-proliferative effects
• CPC Class Codes: G01N 33/5058 Neurological cells
• CPC Class Codes: G01N 33/6896 Neurological disorders, e.g. Alzheimer's disease

Abstract

The present invention describes cell-based screening methods that allow for the elimination of false-positive results due to nonspecific toxicity of test compounds, while detecting those compounds that specifically modulate cellular metabolites in metabolic pathways associated with diseases and disorders, with particular regard to Alzheimer'"'"'s disease. The methods are particularly suited to high-throughput screening techniques to identify compounds (drugs) that are effective in a cell-based system. The methods of the invention involve determining within a cell system the levels of both a metabolic precursor and a metabolite of interest and have broad application in high-throughput drug discovery and identification, particularly for precursor and metabolite molecules which are associated with disease and disease progression, such as Alzheimer'"'"'s disease.

Claims

1. A cell-based screening method to identify compounds that reduce or inhibit the generation of one or more cellular metabolites associated with a disease or disorder, without causing non-specific cytotoxicity, comprising:

(a) contacting cells with a test compound;

(b) determining levels of (i) a cellular precursor protein, or (ii) a conformation state of a cellular precursor protein; and

(c) determining levels of a metabolite generated from (i) or (ii) of step (b);

wherein a compound that specifically reduces or inhibits the level of the metabolite in cells shows a reduction only in the level of the metabolite relative to that in untreated cells, and a compound that is non-specifically cytotoxic shows a reduction in the levels of (i), and, optionally, associated cleavage products of (i);

or of (ii); and

of the metabolite.

2. The method according to claim 1, which is a high-throughput screening method.

3. The method according to claim 1 or claim 2, wherein the method is performed in a single well of a microtiter plate using antibodies directed toward specific epitopes of the metabolite and antibodies directed toward specific epitopes of the precursor protein and, optionally, its associated cleavage products.

4. The method according to claim 1, wherein the determination of the levels of the cellular precursor protein is performed by an enzyme linked immunosorbent assay comprising one or more detectable antibodies specific for epitopes of the cellular precursor protein.

5. The method according to claim 1, wherein the determination of the levels of the metabolite generated by the precursor protein is performed by an enzyme linked immunosorbent assay comprising one or more detectable antibodies specific for epitopes of the metabolite.

6. The method according to claim 1, wherein the cellular precursor protein (i) is amyloid precursor protein (APP) and, optionally, the associated cleavage products are α

carboxy-terminal fragment (α

CTF), β

carboxy-terminal fragment (β

CTF) and γ

carboxy-terminal fragment (γ

CTF).

7. The method according to claim 1, wherein the metabolite is selected from the group consisting of post-translationally modified cellular precursor protein, protein or peptide oligomers, protein or peptide multimers, protofibrillar macromolecules, fibrillar macromolecules and oligomeric assemblies.

8. The method according to claim 1, wherein the metabolite is a proteolytic product of amyloid precursor protein APP.

9. The method according to claim 8, wherein the metabolite is β

carboxy-terminal fragment (β

CTF) or α

carboxy-terminal fragment (α

CTF).

10. The method according to claim 1, wherein the cells contacted with the test compound are selected from primary mammalian cells, mammalian cell lines, neuroblastomas, neurons, isolated brain cells, cells transfected with the gene encoding amyloid precursor protein APP and expressing the encoded APP product, and cells genetically modified to mimic Alzheimer'"'"'s disease pathobiology.

11. The method according to claim 10, wherein the cells are human cells or human cell lines.

12. The method according to claim 1, wherein the test compound is selected from a synthetic organic compound, a chemical compound, a natural product, a polypeptide, or a peptide.

52. The method according to any one of claims 1, 13, 25, 35 and 43, wherein the precursor and the metabolite are detected with labeled antibodies.

53. The method according to claim 52, wherein the antibodies are labeled with a fluorophore, an enzyme, a chemiluminescent molecule, or a radioisotope.

54. A compound that specifically reduces the generation of a metabolite involved in a metabolic pathway associated with disease progression, detected according to the method of claim 1 or claim 13.

55. A compound that specifically increases the generation of a metabolite involved in a metabolic pathway associated with disease progression, detected according to the method of claim 1 or claim 13.

56. A compound that specifically reduces the generation of a metabolite in a proteolytic metabolic pathway associated with Alzheimer'"'"'s disease, as detected by the method according to claim 1, claim 13, claim 25, claim 35, or claim 43.

57. The compound according to claim 56, said compound being 3-methyladenine or functionally related derivatives or analogs thereof.

58. A compound that specifically increases the generation of a metabolite in a proteolytic metabolic pathway associated with Alzheimer'"'"'s disease, as detected by the method according to claim 1, claim 13, claim 25, claim 35, or claim 43.

59. The compound according to claim 58, said compound being α

CTF.

13. A cell-based screening method to identify compounds that increase or augment the generation of one or more cellular metabolites associated with a decreased likelihood of developing, or with a decreased severity of, a disease or disorder, without causing non-specific cytotoxicity, comprising:

(a) contacting cells with a test compound;

(b) determining levels of (i) a cellular precursor protein, or (ii) a conformation state of a cellular precursor protein; and

(c) determining levels of a metabolite generated from (i) or (ii) of step (b);

wherein a compound that specifically increases or augments the level of the metabolite in cells shows an increase in the levels of the metabolite relative to untreated cells, while not significantly changing the levels of (i) or (ii).

14. The method according to claim 13, which is a high-throughput screening method.

15. The method according to claim 13 or claim 14, wherein the method is performed in a single well of a microtiter plate using antibodies directed toward specific epitopes of the metabolite and antibodies directed toward specific epitopes of the precursor protein and, optionally, its associated cleavage products.

16. The method according to claim 13, wherein the determination of the levels of the cellular precursor protein is performed by an enzyme linked immunosorbent assay comprising one or more detectable antibodies specific for epitopes of the cellular precursor protein.

17. The method according to claim 13, wherein the determination of the levels of the metabolite generated by the precursor protein is performed by an enzyme linked immunosorbent assay comprising one or more detectable antibodies specific for epitopes of the metabolite.

18. The method according to claim 15, wherein the cellular precursor protein is amyloid precursor protein (APP), or other proteolytic fragment of APP, and, optionally, the associated cleavage products are α

carboxy-terminal fragment (α

CTF), β

carboxy-terminal fragment (β

CTF) and γ

carboxy-terminal fragment (γ

CTF).

19. The method according to claim 13, wherein the metabolite is selected from the group consisting of post-translationally modified cellular precursor protein, protein or peptide oligomers, protein or peptide multimers, protofibrillar macromolecules, fibrillar macromolecules and oligomeric assemblies.

20. The method according to claim 13, wherein the metabolite is a proteolytic product of amyloid precursor protein APP.

21. The method according to claim 20, wherein the metabolite is secretory APP or α

carboxy-terminal fragment (α

CTF) of APP.

22. The method according to claim 13, wherein the cells contacted with the test compound are selected from primary mammalian cells, cultured mammalian cell lines, neuroblastomas, neurons, isolated brain cells, cells transfected with the gene encoding amyloid precursor protein APP and expressing the encoded APP product, and cells genetically modified to mimic Alzheimer'"'"'s disease pathobiology.

23. The method according to claim 22, wherein the cells are human cells or human cell lines.

24. The method according to claim 13, wherein the test compound is selected from a synthetic organic compound, a chemical compound, a natural product, a polypeptide, or a peptide.

25. A cell-based screening method for distinguishing between a compound that specifically reduces activity of cellular proteolytic pathways involved in metabolic events associated with Alzheimer'"'"'s disease, and a compound that is non-specifically toxic to cells, comprising:

(a) treating cells with a test compound;

(b) detecting levels of one or more amyloid precursor protein (APP) metabolites;

(c) detecting levels of amyloid precursor protein (APP);

(d) comparing the effect of the compound on the levels of the one or more amyloid precursor protein (APP) metabolites and the effect of the compound on the levels of amyloid precursor protein (APP);

wherein a specific reduction in the levels of the one or more amyloid precursor protein (APP) metabolites, with no significant reduction in the levels of the amyloid precursor protein (APP), indicates that the compound specifically inhibits cellular proteolytic pathways and is not non-specifically cytotoxic.

26. The method according to claim 25, which is a high-throughput screening method.

27. The method according to claim 25, wherein, in step (b), the one or more amyloid precursor protein (APP) metabolites is cell-associated β

carboxy-terminal fragment (β

CTF) resulting from proteolytic processing of amyloid precursor protein APP.

28. The method according to claim 25, further wherein, in step (c), proteolytic fragments comprising α

carboxy-terminal fragment (α

CTF), β

carboxy-terminal fragment (β

CTF) and γ

carboxy-terminal fragment (γ

CTF) of the amyloid precursor protein (APP) are detected.

29. The method according to claim 25 or 26, wherein the method is performed in a single well of a microtiter plate using antibodies directed toward specific epitopes of the one or more amyloid precursor protein (APP) metabolites and antibodies directed toward specific epitopes of amyloid precursor protein (APP).

30. The method according to claim 25, wherein the determination of the levels of the one or more amyloid precursor protein (APP) metabolites is performed by an enzyme linked immunosorbent assay comprising one or more detectable antibodies specific for epitopes on the one or more APP metabolites.

31. The method according to claim 25, wherein the determination of the levels of the amyloid precursor protein (APP) is performed by an enzyme linked immunosorbent assay comprising one or more detectable antibodies specific for epitopes on the amyloid precursor protein (APP).

32. The method according to claim 25, wherein the cells contacted with the test compound are selected from primary mammalian cells, cultured mammalian cell lines, neuroblastomas, neurons, isolated brain cells, cells transfected with the gene encoding amyloid precursor protein APP and expressing the encoded APP product, and cells genetically modified to mimic Alzheimer'"'"'s disease pathobiology.

33. The method according to claim 32, wherein the cells are human cells or human cell lines.

34. The method according to claim 25, wherein the test compound is selected from a synthetic organic compound, a chemical compound, a natural product, a polypeptide, or a peptide.

35. A cell-based screening method for distinguishing between a compound that specifically reduces activity of cellular proteolytic pathways involved in metabolic events associated with Alzheimer'"'"'s disease, and a compound that is non-specifically toxic to cells, comprising:

(a) treating cells with a test compound;

(b) detecting levels of cell-associated β

carboxy-terminal fragment (β

CTF) resulting from proteolytic processing of amyloid precursor protein APP;

(c) detecting levels of amyloid precursor protein (APP) and its associated cleavage fragments comprising α

carboxy-terminal fragment (α

CTF), β

carboxy-terminal fragment (β

CTF) and γ

carboxy-terminal fragment (γ

CTF);

(d) comparing the effect of the compound on the levels of β

CTF generated from the cleavage of APP and the effect of the compound on the levels of amyloid precursor protein (APP) and its associated cleavage, fragments;

wherein a specific reduction in the levels of β

CTF, with no significant reduction in the levels of amyloid precursor protein (APP) and its associated cleavage fragments relative to control, indicates that the compound specifically inhibits cellular proteolytic pathways and is not non-specifically cytotoxic.

36. The method according to claim 35, which is a high-throughput screening method.

37. The method according to claim 35 or claim 36, wherein the method is performed in a single well of a microtiter plate using antibodies directed toward specific epitopes of the β

carboxy-terminal fragment (β

CTF) and antibodies directed toward specific epitopes of amyloid precursor protein (APP) and its associated cleavage fragments.

38. The method according to claim 35, wherein the determination of the levels of the cell-associated β

carboxy-terminal fragment (β

CTF) resulting from the proteolytic processing of amyloid precursor protein APP is performed by an enzyme linked immunosorbent assay comprising one or more detectable antibodies specific for epitopes on the cell-associated β

carboxy-terminal fragment (β

CTF).

39. The method according to claim 35, wherein the determination of the levels of the amyloid precursor protein (APP) and its associated cleavage fragments is performed by an enzyme linked immunosorbent assay comprising one or more detectable antibodies specific for epitopes on the amyloid precursor protein (APP) and its associated cleavage fragments.

40. The method according to claim 35, wherein the cells treated with the test compound are selected from primary mammalian cells, cultured mammalian cell lines, neuroblastomas, neurons, isolated brain cells, cells transfected with the gene encoding amyloid precursor protein APP and expressing the encoded APP product, and cells genetically modified to mimic Alzheimer'"'"'s disease pathobiology.

41. The method according to claim 40, wherein the cells are human cells or human cell lines.

42. The method according to claim 35, wherein the test compound is selected from a synthetic organic compound, a chemical compound, a natural product, a polypeptide, or a peptide.

43. A cell-based screening method to identify compounds that reduce or inhibit the activity of cellular metabolites involved in an Alzheimer'"'"'s disease metabolic pathway, comprising:

(a) treating with a test compound cells plated onto a substrate coated with one or more capture antibodies directed against amyloid precursor protein (APP) and APP cell associated metabolites;

(b) disrupting the cells, wherein extracted amyloid precursor protein (APP) and APP cell associated metabolites bind to the one or more capture antibodies;

(c) detecting binding of protein to capture antibody with detection antibodies, wherein the detection antibodies comprise (i) labeled antibodies that specifically recognize one or more APP metabolites and (ii) differently labeled antibodies that specifically recognize amyloid precursor protein (APP) and, optionally, carboxy-terminal, proteolytic products thereof; and

(d) determining the levels of (i) the one or more APP metabolites, and (ii) the amyloid precursor protein (APP) and, optionally, the carboxy-terminal proteolytic products thereof;

wherein a decrease in the levels of the one or more APP metabolites, without a significant decrease in the level of the APP protein, and optionally, the carboxy-terminal proteolytic products thereof, relative to untreated cells, indicates that the compound specifically inhibits cellular proteolytic pathways and is not non-specifically cytotoxic.

44. The method according to claim 43, which is a high-throughput screening method.

45. The method according to claim 43, wherein the capture antibody is directed against the carboxy-terminus of the amyloid precursor protein (APP).

46. The method according to claim 43, wherein the one or more APP metabolites is selected from β

CTF, α

CTF and γ

CTF.

47. The method according to claim 43, wherein the one or more APP metabolites is β

CTF.

48. The method according to claim 43, wherein the cells treated with the test compound are selected from primary mammalian cells, cultured mammalian cell lines, neuroblastomas, neurons, isolated brain cells, cells transfected with the gene encoding amyloid precursor protein APP and expressing the encoded APP product, and cells genetically modified to mimic Alzheimer'"'"'s disease pathobiology.

49. The method according to claim 48, wherein the cells are human cells or human cell lines.

50. The method according to claim 43, wherein the test compound is selected from a synthetic organic compound, a chemical compound, a natural product, a polypeptide, or a peptide.

51. The method according to claim 43, wherein the detection antibodies are labeled with different fluorophores.

60. A kit for detecting compounds which specifically reduce or increase a cellular metabolite in a pathway associated with a disease or disorder, and which are not generally toxic to cells, comprising containers comprising one or more detectable reagents to determine levels of (i) a cellular metabolic precursor protein or (ii) a conformation state of a cellular precursor protein;

and (iii) one or more metabolites of the precursor protein of (i) or (ii); and

instructions for use.

61. The kit according to claim 60, wherein the detectable reagents comprise one or more labeled or unlabeled antibodies specific for the metabolic precursor protein and labeled or unlabeled antibodies specific for the one or more metabolites;

and further comprising one or more labeled secondary antibodies for differential detection of the unlabeled specific antibodies.